The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Scientists are unraveling the mystery of what triggers Huntington’s disease, a devastating hereditary disorder that strikes in the prime of life Scientists are unraveling the mystery of what ...

Omvoh’s safety profile in patients with moderate to severe Crohn’s disease aligns with previous findings in patients with ulcerative colitis. The most common side effects include upper ...

Lilly Research Laboratories and Lilly Immunology chief scientific officer, and president Daniel Skovronsky stated: “With Omvoh approved in both Crohn’s disease and ulcerative colitis, more patients ...

This approval follows the drug's previous sanction for ulcerative colitis in October 2023 ... a significant aspect of Crohn's disease pathology. The FDA's decision is based on results from the Phase 3 ...

The FDA ap­proved Eli Lil­ly’s Omvoh in Crohn’s dis­ease, the com­pa­ny an­nounced Wednes­day, hand­ing the drug its sec­ond in­di­ca­tion af­ter giv­ing it a green light … ...

This approval follows the drug's previous sanction for ulcerative colitis in October 2023 ... a significant aspect of Crohn's disease pathology. The FDA's decision is based on results from ...